TMS Co., Ltd. (4891.T)
JPY 220.0
(0.0%)
JPY 220.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 943.25 Million JPY | 81.34% |
| 2022 | 520.14 Million JPY | -35.85% |
| 2021 | 810.88 Million JPY | 12.44% |
| 2020 | 721.15 Million JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 220 Million JPY | -41.6% |
| 2024 Q2 | 228.98 Million JPY | 4.08% |
| 2023 Q1 | 151.76 Million JPY | 41.13% |
| 2023 Q4 | 376.74 Million JPY | 70.17% |
| 2023 FY | 943.25 Million JPY | 81.34% |
| 2023 Q2 | 193.34 Million JPY | 27.4% |
| 2023 Q3 | 221.39 Million JPY | 14.51% |
| 2022 Q2 | 234.5 Million JPY | 0.0% |
| 2022 FY | 520.14 Million JPY | -35.85% |
| 2022 Q4 | 107.53 Million JPY | -62.14% |
| 2022 Q3 | 284 Million JPY | 21.11% |
| 2021 FY | 810.88 Million JPY | 12.44% |
| 2020 FY | 721.15 Million JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.28 Billion JPY | 26.565% |
| PRISM BioLab Co.,LTD | 576.81 Million JPY | -63.528% |
| GNI Group Ltd. | 9.32 Billion JPY | 89.882% |
| Linical Co., Ltd. | 2.7 Billion JPY | 65.132% |
| Trans Genic Inc. | 2.15 Billion JPY | 56.327% |
| MEDINET Co., Ltd. | 1.49 Billion JPY | 36.744% |
| Soiken Holdings Inc. | 3.07 Billion JPY | 69.286% |
| Cytori Cell Research Institute, Inc. | 1.85 Billion JPY | 49.205% |
| AnGes, Inc. | 8.9 Billion JPY | 89.404% |
| OncoTherapy Science, Inc. | 943.08 Million JPY | -0.018% |
| Nxera Pharma Co., Ltd. | 19.19 Billion JPY | 95.085% |
| Immuno-Biological Laboratories Co., Ltd. | 412.99 Million JPY | -128.396% |
| NanoCarrier Co., Ltd. | 975.37 Million JPY | 3.293% |
| Carna Biosciences, Inc. | 2.56 Billion JPY | 63.263% |
| CanBas Co., Ltd. | 278 Million JPY | -239.3% |
| D. Western Therapeutics Institute, Inc. | 1.14 Billion JPY | 17.37% |
| RaQualia Pharma Inc. | 1.81 Billion JPY | 48.114% |
| Chiome Bioscience Inc. | 1.6 Billion JPY | 41.185% |
| Kidswell Bio Corporation | 2.37 Billion JPY | 60.268% |
| PeptiDream Inc. | 9.68 Billion JPY | 90.263% |
| Oncolys BioPharma Inc. | 1.96 Billion JPY | 51.889% |
| Ribomic Inc. | 1.1 Billion JPY | 14.691% |
| SanBio Company Limited | 4.53 Billion JPY | 79.219% |
| Healios K.K. | 3.48 Billion JPY | 72.949% |
| BrightPath Biotherapeutics Co., Ltd. | 1.15 Billion JPY | 18.315% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 1.33 Billion JPY | 29.316% |
| Delta-Fly Pharma, Inc. | 1.4 Billion JPY | 32.791% |
| StemRIM | 2.07 Billion JPY | 54.564% |
| CellSource Co., Ltd. | 1.96 Billion JPY | 51.961% |
| FunPep Company Limited | 313.82 Million JPY | -200.57% |
| Kringle Pharma, Inc. | 958.01 Million JPY | 1.541% |
| Stella Pharma Corporation | 963.98 Million JPY | 2.151% |
| Noile-Immune Biotech Inc. | 1.08 Billion JPY | 13.459% |
| Cuorips Inc. | 598.11 Million JPY | -57.703% |
| K Pharma,Inc. | 543.94 Million JPY | -73.411% |
| Takara Bio Inc. | 23.9 Billion JPY | 96.054% |
| ReproCELL Incorporated | 1.51 Billion JPY | 37.699% |
| PhoenixBio Co., Ltd. | 1.18 Billion JPY | 20.333% |
| StemCell Institute Inc. | 1.16 Billion JPY | 18.834% |
| Japan Tissue Engineering Co., Ltd. | 1.52 Billion JPY | 38.037% |
| CellSeed Inc. | 804.93 Million JPY | -17.184% |